Itagaki et al., 2017 - Google Patents
Intratracheal instillation of neutrophils rescues bacterial overgrowth initiated by trauma damage-associated molecular patternsItagaki et al., 2017
View HTML- Document ID
- 15750296850364286732
- Author
- Itagaki K
- Riça I
- Zhang J
- Gallo D
- DePrato M
- Otterbein L
- Hauser C
- Publication year
- Publication venue
- Journal of Trauma and Acute Care Surgery
External Links
Snippet
BACKGROUND Nosocomial pneumonias are common in trauma patients and so interventions to prevent and treat nosocomial pneumonia may improve outcomes. Our prior work strongly suggests that tissue injury predisposes to infections like nosocomial …
- 208000014674 injury 0 title abstract description 78
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Limitations of phage therapy and corresponding optimization strategies: a review | |
| Ryan et al. | Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy | |
| Soothill | Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections | |
| Kwiatek et al. | Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections–an in vivo studies overview | |
| Abd El-Aziz et al. | Bacteriophage therapy increases complement-mediated lysis of bacteria and enhances bacterial clearance after acute lung infection with multidrug-resistant Pseudomonas aeruginosa | |
| Maura et al. | Bacteriophages as twenty-first century antibacterial tools for food and medicine | |
| Capparelli et al. | Experimental phage therapy against Staphylococcus aureus in mice | |
| Gelman et al. | The history and promising future of phage therapy in the military service | |
| Senhaji-Kacha et al. | Considerations for phage therapy against Mycobacterium abscessus | |
| JP2013049700A (en) | Therapeutic agent containing bacteriophage | |
| Manohar et al. | Pharmacological and immunological aspects of phage therapy | |
| US5676977A (en) | Method of curing AIDS with tetrasilver tetroxide molecular crystal devices | |
| Squires | Bacteriophage therapy for management of bacterial infections in veterinary practice: what was once old is new again | |
| Itagaki et al. | Intratracheal instillation of neutrophils rescues bacterial overgrowth initiated by trauma damage-associated molecular patterns | |
| Mehmood Khan et al. | The applications of animal models in phage therapy: an update | |
| Filippov et al. | Can phage effectively treat multidrug-resistant plague? | |
| Leitner et al. | Bacteriophages: a panacea in neuro-urology? | |
| Valente et al. | Progress and pitfalls of bacteriophage therapy in critical care: A concise definitive review | |
| Krishnan et al. | Serotype O18 avian pathogenic and neonatal meningitis Escherichia coli strains employ similar pathogenic strategies for the onset of meningitis | |
| Linde et al. | Conserved structure and function in the granulysin and NK-lysin peptide family | |
| Martins et al. | Clinical utilization of bacteriophages: a new perspective to combat the antimicrobial resistance in Brazil | |
| Shanks et al. | Predatory prokaryotes wage war against eye infections | |
| Heine et al. | Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax | |
| Uchiyama et al. | Blood kinetics of four intraperitoneally administered therapeutic candidate bacteriophages in healthy and neutropenic mice | |
| LASHTOO et al. | Conventional Treatment of burn wound infections versus phage therapy |